IceCure Medical Bolsters U.S. Team to Cater to Rising ProSense® Cryoablation Demand

IceCure Expands Sales and Marketing Teams in the U.S.

IceCure Medical Ltd. (Nasdaq: ICCM), a pioneer in the field of cryoablation technology that utilizes liquid nitrogen to destroy tumors, has announced a substantial expansion of its U.S. commercial team. This move comes as a response to a noticeable increase in demand for its flagship product, ProSense®, particularly among leading hospitals and physicians throughout the country.

In recent months, the company has seen an impressive 70% increase in its active commercial installations of ProSense®, a trend largely attributed to the U.S. Food and Drug Administration's (FDA) marketing authorization received in October 2025. This milestone has paved the way for wider clinical acceptance and has been supported by updated clinical guidelines that endorse the use of cryoablation as an effective treatment for breast cancer.

With this expansion, IceCure has brought in new members to its sales and marketing teams, specifically focusing on strategic regions such as New York, Southern California, and the Midwest. These regions have been identified as key areas for the implementation of their advanced cryoablation technology. Furthermore, the company has enhanced its clinical support teams to ensure comprehensive training and increased adoption of ProSense® in both new and existing medical facilities.

IceCure Medical's Chief Executive Officer, Eyal Shamir, expressed optimism about the company’s growth trajectory: "We are pleased with the strong traction and increasing momentum we are experiencing in the U.S. market. We continue our commercialization efforts in order to raise awareness of our innovative cryoablation treatment and make it available to patients in additional territories and regions."

One of the significant factors contributing to the surge in interest surrounds the efficiency and effectiveness of the ProSense® system. As a minimally invasive alternative to surgical tumor removal, the ProSense® device provides a safe, quick, and manageable option for patients. This appeal is reflected in the growing number of major metropolitan areas where cryoablation procedures are now being performed, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, and Phoenix.

The technology itself is grounded in cryoablation protocols that allow for the targeted destruction of both benign and malignant tumors. IceCure’s innovative approach emphasizes the importance of patient safety and comfort during treatments. As the healthcare landscape continues to evolve, there is an ongoing push towards less invasive treatment options, making IceCure's solutions more relevant than ever.

Shamir further noted the importance of maintaining and developing relationships with healthcare providers: "Our goal as we expand our teams is not just to sell ProSense® systems, but to ensure that every physician is well-informed and confident about implementing this technology into their practices. This education is vital for the continued growth of our market share."

As IceCure continues to adapt to the changing needs of healthcare professionals and patients alike, the company's proactive strategy mirrors a broader trend in the industry focused on enhancing the quality of patient care through innovative technology.

In summary, the recent expansion of IceCure Medical's U.S. commercial team is a significant step towards meeting the rising demand for ProSense® cryoablation therapy, reflecting both the company's commitment to innovation and its responsive approach to market needs. As IceCure continues to grow, its contributions to the field of cryoablation could potentially change how tumor management is understood and treated around the world.